Starling Oncology, Inc. Common Stock (STLN)

Is Starling Oncology, Inc. Common Stock (STLN) A Buy Now?

According to our latest analysis, STLN could be considered a Strong Buy, with 17 technical analysis indicators signaling 10 Buy signals, 3 signaling Sell signals and 4 Neutral signals. This might be a good time to open fresh positions on STLN, as trading bullish markets is always a lot easier

1. RSI (Relative Strength Index): The RSI(14) value of 55.44 indicates that STLN is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
2. STOCH (Stochastic Oscillator): The STOCH value of 45.45 indicates that STLN is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
3. STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 85.35 indicates that STLN is overbought. This suggests that STLN price is at or near the highest level relative to its recent price history.
4. ADX (Average Directional Index): The ADX value of 22.20 suggests a moderate trend in the market. While not exceptionally strong, it indicates that there is some directional movement occurring. You should pay attention to this trend but may also look for confirmation from other technical indicators or fundamental factors.
5. CCI (Commodity Channel Index): A CCI(14) value of 50.30 indicates that STLN is still overbought but not to an extreme extent.

Long-term STLN price forecast for 2026, 2030, 2035, 2040, 2045 and 2050

Based on our analysis about Starling Oncology, Inc. Common Stock financial reports and earnings history, Starling Oncology, Inc. Common Stock (STLN) stock could reach $6.36 by 2030, $4.06 by 2040 and $1.77 by 2050. See the projected annual prices until 2050 of the Starling Oncology, Inc. Common Stock stock below:

• Starling Oncology, Inc. Common Stock (STLN) is expected to reach an average price of $4.63 in 2035, with a high prediction of $5.18 and a low estimate of $2.75. This indicates an -32.23% change from the last recorded price of $6.83.
• Starling Oncology, Inc. Common Stock (STLN) stock is projected to chart a bullish course in 2040, with an average price target of $3.18, representing an -53.45% change from its current level. The forecast ranges from a conservative $1.56 to a sky-high $4.06.
• Our analysts predict Starling Oncology, Inc. Common Stock (STLN) to change -73.97% by 2045, soaring from $0.44 to an average price of $1.78, potentially reaching $2.95. While $0.44 is the low estimate, the potential upside is significant.
• Starling Oncology, Inc. Common Stock (STLN) stock is expected to climb by 2050, reaching an average of $1.14, a -83.29% change from its current level. However, a wide range of estimates exists, with high and low targets of $1.77 and $0.2451, respectively, highlighting the market's uncertainty.

Starling Oncology, Inc. Common Stock Stock (STLN) Year by Year Forecast